Toggle Offcanvas
...
 
Infliximab Tenders

Infliximab Tenders

View Infliximab tenders, RFPs and contracts. Bid on readily available Infliximab tenders with the best and most comprehensive tendering platform, since 2002.

Bidding for Infliximab tenders is extremely lucrative for companies of all sizes. Tendering authorities and private companies release thousands of contracts worth millions for procurement of Infliximab.

Global Tenders stands out as the largest platform dedicated to pharmaceutical tenders and government contracts. Boasting over 20 years of experience in the tender business, GlobalTenders offers the most extensive and reliable Tenders/RFPs/Contracts Database available. The platform aggregates contracts from both public and private sources, connecting with a vast network of over half a million buyers. Employing advanced artificial intelligence, our meticulous process involves gathering information from over a hundred thousand sources. The data is then intelligently categorized into thousands of subcategories for easy filtering and presenting it in a user-friendly format for quick comprehension.

In addition to tender information, we offer in-depth Infliximab market analysis, bid consultancy services, and insights into top bidders and winners.

Sign up now to get instant access to unlimited Infliximab tenders, advanced search filters, market analysis, industry trends, tender training and 24/7 customer support.

25 Live Notices for Infliximab Tenders

Showing 1 to 20

Infliximab 100 Mg Liof P Sol Inyec Fam 1000021622
country Chile
posting date02 Sep 2025
deadline15 Sep 2025
Specific Contract For The Supply Of Exclusive And/Or Infungable Drugs Through The Use Of The Sintel Platform, Pursuant To Art. 55, Paragraph 8 Of Legislative Decree 50/2016, As Part Of The Dynamic Acquisition System Called Aria2020305 "Dynamic Acquisition System For Supplies Of Pharmaceutical Products" - 5Th Procedure Year 2025
country Italy
posting date09 Jul 2025
deadline08 Sep 2025
Completion Of A Non-Exclusive Discount Contract According To Section 130A (8) Sgb V On Pharmaceuticals With The Active Ingredient Infliximab (Atc Code: L04Ab02).
country Germany
posting date06 Jun 2025
deadline27 May 2027
Completion Not Excl. Pharmaceutical Discount Club. According To Section 130A (8) Sgb V By Means Of An Open House Model To The Active Ingredient Infliximab (Atc Code According To Who: L04Ab02)
country Germany
posting date25 Mar 2025
deadline30 Apr 2027
Completion Not Excl. Pharmaceutical Discount Club. According To Section 130A (8) Sgb V By Means Of An Open House Model To The Active Ingredient Infliximab (Atc Code According To Who: L04Ab02)
country Germany
posting date25 Mar 2025
deadline30 Apr 2027
Completion Of Non-Exclusive Discount Agreements According To § 130 A (8) Sgb V With The Active Ingredient Infliximab For Subcutaneous Application
country Germany
posting date01 Mar 2025
deadline10 Feb 2027
Completion Of Non-Exclusive Discount Agreements According To § 130 A (8) Sgb V With The Active Ingredient Infliximab For Intravenous Application
country Germany
posting date01 Mar 2025
deadline10 Feb 2027
Completion Of Non-Exclusive Discount Agreements According To § 130 A (8) Sgb V With The Active Ingredient Infliximab For Subcutaneous Application
country Germany
posting date28 Feb 2025
deadline10 Feb 2027
Open House Biologics Discount Agreements 2025-01 - Infliximab
country Germany
posting date13 Feb 2025
deadline31 Mar 2027
Open House Biologics Discount Agreements 2025-01 - Infliximab
country Germany
posting date13 Feb 2025
deadline31 Mar 2027
Environmentally Friendly Supply Of Biological Human Medicines With Biosimilars For Public Health Centres In Valencia
country Spain
posting date30 Dec 2024
deadline01 Oct 2025
Conclusion Of Non-Exclusive Discount Agreements According To §130A Para.8 Sgb V For Various Active Ingredients/Combinations With The Possibility Of Conclusion At Any Time Within The Framework Of The So-Called Open House Procedure
country Germany
posting date05 Dec 2024
deadline05 Dec 2026
Conclusion Of Non-Exclusive Discount Agreements According To §130A Para.8 Sgb V For Various Active Ingredients/Combinations With The Possibility Of Conclusion At Any Time Within The Framework Of The So-Called Open House Procedure
country Germany
posting date26 Nov 2024
deadline05 Dec 2026
Conclusion Of A Non-Exclusive Drug Discount Agreement Pursuant To Section 130A Paragraph 8 Of The Social Code Book V By Means Of An Open-House Model For The Active Ingredient Infliximab For Subcutaneous Injection (Atc Code According To Who: L04Ab02)
country Germany
posting date11 Nov 2024
deadline31 Dec 2026
Pharmaceutical Discount Agreements From 01.01.2025 For Various Active Ingredients Within The Framework Of An Open-House Procedure
country Germany
posting date11 Nov 2024
deadline02 Nov 2026
Conclusion Of A Non-Exclusive Drug Discount Agreement Pursuant To Section 130A Paragraph 8 Of The Social Code Book V By Means Of An Open-House Model For The Active Ingredient Infliximab For Subcutaneous Injection (Atc Code According To Who: L04Ab02)
country Germany
posting date11 Nov 2024
deadline31 Dec 2026
Pharmaceutical Discount Agreements From 01.01.2025 For Various Active Ingredients Within The Framework Of An Open-House Procedure
country Germany
posting date11 Nov 2024
deadline02 Nov 2026
Conclusion Of A Non-Exclusive Drug Discount Agreement Pursuant To Section 130A Paragraph 8 Of The Social Code Book V By Means Of An Open-House Model For The Active Ingredient Infliximab For Subcutaneous Injection (Atc Code According To Who: L04Ab02)
country Germany
posting date11 Nov 2024
deadline31 Dec 2026
Pharmaceutical Discount Agreements From 01.01.2025 For Various Active Ingredients Within The Framework Of An Open-House Procedure
country Germany
posting date11 Nov 2024
deadline02 Nov 2026
Open House Drug Rebate Agreements Infliximab, Atc L04Ab02
country Germany
posting date17 Sep 2024
deadline05 Sep 2026

Share Share this page